Long-term year beneficial effects beta-adrenergic blockade bucindolol patients idiopathic cardiomyopathy Beta-adrenergic blockade promising therapeutic approach cardiomyopathy Bucindolol new beta-blocker favorable effects short-term month trial idiopathic cardiomyopathy long-term response study patients patients placebo group patients therapy long-term bucindolol therapy mean months mean patient age years median duration disease months patients functional class II class III patients men end common follow-up time patients alive bucindolol mean mg/day underwent cardiac transplantation Left ventricular ejection fraction baseline value pairs Functional class unchanged Exercise time versus min NS maximal oxygen uptake versus ml/kg min NS long-term bucindolol therapy substantial increases ejection fraction functional class stable exercise performance 